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Abstract
Background: Intramuscular injections of botulinum toxin A (BoNT-A) have been a cornerstone in the treatment of
spasticity for the last 20 years. In Norway, the treatment is now offered to two out of three children with spastic
cerebral palsy (CP). However, despite its common use, the evidence for its functional effects is limited and inconclusive.
The objective of this study is to determine whether BoNT-A makes walking easier in children with CP. We hypothesize
that injections with BoNT-A in the calf muscles will reduce energy cost during walking, improve walking capacity,
increase habitual physical activity, reduce pain and improve self-perceived performance and satisfaction.
Methods/design: This randomized, double-blinded, placebo-controlled, multicenter trial is conducted in a clinical
setting involving three health regions in Norway. Ninety-six children with spastic CP, referred for single-level injections
with BoNT-A in the calf muscles, will be invited to participate. Those who are enrolled will be randomized to receive
either injections with BoNT-A (Botox®) or 0.9% saline in the calf muscles. Stratification according to age and study
center will be made. The allocation ratio will be 1:1. Main inclusion criteria are (1) age 4 − 17.5 years, (2) Gross Motor
Function Classification System levels I and II, (3) no BoNT-A injections in the lower limbs during the past 6 months and
(4) no orthopedic surgery to the lower limbs during the past 2 years. The outcome measures will be made at baseline
and 4, 12 (primary endpoint) and 24 weeks after injections. Primary outcome is change in energy cost during walking.
Secondary outcomes are change in walking capacity, change in activity, perceived change in performance and
satisfaction in mobility tasks, and pain. The primary analysis will use a linear mixed model to test for difference in
change in the outcome measures between the groups. The study is approved by the Regional Ethical Committee and
The Norwegian Medicines Agency. Recruitment started in September 2015.
Discussion: The evaluation of effect is comprehensive and includes objective standardized tests and measures on
both impairment and activity level. Results are to be expected by spring 2019.
Trial registration: ClinicalTrials.gov, NCT02546999. Registered on 9 September 2015.
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Background
Cerebral palsy (CP) is the most common cause of neuro-
logical disability in childhood, and the motor signs associ-
ated with the condition include primary neuromuscular
deficits, such as spasticity, muscle weakness, and decreased
selective motor control, and secondary musculoskeletal
problems such as bony malformations and contractures [1].
Impaired walking is a main clinical feature of CP, and al-
though approximately 70% of children with CP are able to
walk, they all experience varying degrees of restrictions re-
lated to this function [2]. Such restrictions include re-
duced walking speed [3], impaired balance [4] and high
energy costs (ECs) during walking [5]. The ECs during
walking increase with increasing level of disability [6] and
age [7], and these impairments may, therefore, in part
contribute to fatigue; a common complaint in children
and youths with CP [8]. Moreover, recurrent musculoskel-
etal pain is common, affecting both general activity and
walking [9, 10]. As a consequence, children with CP are in
general less active than their peers, and they less often
take part in social activities [11].
The dominating motor disorder in CP is spasticity, de-
fined as a velocity-dependent increase in resistance to
passive movement [12], present in more than 80% of the
children [2]. The introduction of intramuscular injec-
tions of botulinum toxin A (BoNT-A) in the 1990s rep-
resented a significant breakthrough in the treatment of
spasticity. BoNT-A is a neuromuscular paralyzing agent
and it results in a dose-dependent chemo-denervation of
the muscle by inhibiting the release of the neurotrans-
mitter acetylcholine at the neuromuscular junction. Cur-
rently, treatment with BoNT-A is offered to as many as
two thirds of all children with spastic CP and more than
half of the children are able to walk independently [13].
Among children able to walk, a main goal of this
treatment is to improve gait [14], and thereby improving
the potential for higher levels of activity and participa-
tion. It is well-documented that BoNT-A reduces spasti-
city [15, 16]; however, despite being commonly used,
evidence for functional effects is limited and inconclu-
sive [17, 18]. In a systematic review [19], including eight
randomized control trials (RCTs) the effects on walking
were specifically addressed. The authors found that five
of the eight studies were of low methodological quality,
and seven got low scores on clinical relevance. The main
limitations of the included studies related to differences
in outcome measures, lack of a-priori defined effect
sizes, and variations in follow-up time. The authors of
the systematic review, therefore, had to rely on their
“general impression” of improvement in “any functional
outcome.” Based on this “general impression” the au-
thors concluded that the use of BoNT-A with usual care
or physiotherapy seemed to improve walking of children
with CP emphasizing that their conclusions should be
appraised carefully owing to the limited quality of in-
cluded trials. Other long-term follow-up studies, taking
a pragmatic approach in order to reflect clinical practice,
were unable to document cumulative or persistent bene-
fit on walking of repeated BoNT-A injections [20]. Thus,
a fair summary of the existing medical literature is that
the evidence for an effect of BoNT-A injections in the
leg muscles on walking is limited and inconclusive.
The main objective of the current trial is, therefore, to in-
vestigate whether injections of BoNT-A in the calf muscles
(m. gastrocnemius and m. soleus) make walking easier in
children and adolescents with CP within a time span of
6 months, as judged by reduced EC during walking. Sec-
ondary objectives are to explore whether injections of
BoNT-A increase activity, improve walking capacity, de-
crease musculoskeletal pain, and improve perceived per-
formance and satisfaction related to mobility tasks.
We hypothesize that injections of BoNT-A in the calf
muscles will reduce EC during walking, improve walking
capacity, increase habitual physical activity and reduce
pain. Moreover, we hypothesize that injections with
BoNT-A will improve perceived performance and satis-
faction related to ambulation. Secondary, we hypothesize
that younger children and children with lower gross
motor function will improve more in EC than older chil-
dren and children with greater gross motor function.
In a substudy of this RCT, we aim to identify different
CP phenotypes of responders to BoNT-A treatment and,
moreover, to gain insight into the processes underlying
BoNT-A-induced changes in walking. On that account,
we want to identify gait and muscle activation patterns,
spasticity and strength characteristics related to the re-
sponse of BoNT-A on our primary and secondary out-
come measures. Moreover, semistructured qualitative
interviews will be conducted on a subset of participants
(minimum 25) and their parents. Details of these studies
are not presented in this paper.
Methods/design
Study design and setting
The WE-Study is designed as an industry-independent,
double-blinded, placebo-controlled, superiority trial
where participants are randomized to receive either in-
jections of BoNT-A or saline (placebo) in the calf mus-
cles. The allocation ratio will be 1:1. It is a multicenter
study conducted in a clinical setting, involving three out
of four health regions in Norway as well as the Norwe-
gian University of Science and Technology, NTNU. The
study will be conducted according to the Declaration of
Helsinki and ICH-Good Clinical Practice guidelines. The
study protocol follows the SPIRIT 2013 (Standard Proto-
col Items: Recommendations for Interventional Trials)
guidelines [21]. The SPIRIT Checklist (Additional file 1)
and figure (Table 1) are provided.
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Monitoring will be carried out according to a predefined
plan, independent of the sponsor and with no competing
interests. Protocol modifications will be reviewed by the
Regional Ethics Committee (REC). Substantial modifica-
tions will also be reviewed by The Norwegian Medicines
Agency. Processing of personal study data will be done ac-
cording to procedures approved by the data protection of-
ficial at each study center. The trial registration data are
provided in Table 2.
Participants
Eligible to participate are children and adolescents between
4 and 17.5 years of age (at the time of inclusion) with spas-
tic unilateral or bilateral CP. The gross motor function of
the participants should be at levels I or II according to the
Gross Motor Function Classification System (GMFCS) [22]
and they should not have been treated with BoNT-A in the
lower limbs during the past 6 months or have undergone
orthopedic surgery to the lower limbs in the last 2 years
prior to study participation. Moreover, participants must be
able to take verbal instructions. Exclusions are made based
on the following criteria: history of prior adverse reactions
to BoNT-A, presence of infection at the proposed injection
site(s), subclinical or clinical evidence of defective neuro-
muscular transmission or other underlying neurological
disorders that may be affected by BoNT-A injections, use
of aminoglycoside antibiotics or spectinomycin, or other
medicinal products that interfere with neuromuscular
transmission (e.g., neuromuscular blocking agents), women
with childbearing potential not using contraception, preg-
nant or breastfeeding women, children needing deep
sedation, or any other reason in the opinion of the
Table 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure
Study period
Enrolment Allocation Post allocation Close-out







Botulinum toxin A x
Assessments:
Energy cost x x x x
Habitual physical activity x x x x
Pain x x x x
Perceived change in performance and satisfaction x x x x
Spasticity test x x x x
Passive range of motion in the ankle x x x x
Table 2 Trial registration data
Data category Information





The Norwegian Medicines Agency 14/15799-9
Sponsor St. Olav’s University Hospital, Trondheim, Norway
Contact Siri.merete.brendvik@stolav.no
Short title The WE-Study (Walking Easier with cerebral
palsy)
Scientific title Does botulinum toxin A make walking easier in




Population Children with cerebral palsy (4 − 17.5 years)
Intervention Active comparator: botulinum toxin A (Botox®)
Placebo comparator: saline
Study type Interventional parallel-group, randomized,
double-blinded
Phase IV
Primary purpose: treatment effect
First enrollment September 2015
Target sample size 96
Primary outcome Energy cost during walking
Secondary outcome Activity, pain, walking capacity, perceived benefit
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investigator. Children who receive concurrent injections in
the upper limbs may be included in the study. Each study
center will have one person in the study team responsible
for introducing eligible participants to the study and the in-
formation given will be both orally and written. The same
person will be responsible for obtaining written consent be-
fore baseline testing.
Once enrolled in the study, every reasonable effort will be
made to avoid dropout and there will be close communica-
tion with participants and caregivers in the follow-up
period. Patients may be discontinued from study treatment
and assessments at any time. Specific reasons for discon-
tinuing a patient for this study are: voluntary discontinu-
ation by the patient, safety reason as judged by the
principal investigator, major protocol deviation, incorrect
enrollment, i.e., the patient does not meet the required in-
clusion/exclusion criteria for the study, deterioration in the
patient’s condition which, in the opinion of the principal in-
vestigator, warrants study discontinuation (to be recorded
as an adverse event; AE) and patient noncompliance to
study treatment and/or procedures. Reason for discontinu-
ation will be recorded in the web-based Case Report Form
(eCRF) used in the study, and the participant will be offered
an assessment including both primary and secondary out-
comes before leaving the trial. After completing the study
period, the participants will continue their regular follow-
up at the hospital. Insurance coverage for this study is made
through membership of the Drug Liability Association.
Randomization and blinding
Eligible participants who have provided informed con-
sent, either on behalf of themselves, by proxy (parents)
or both, are randomized to either injections of BoNT-A
or saline. The randomization will be performed using
prerandomized lists at the four study centers, made by
the unit of Applied Clinical Research at the Norwegian
University of Science and Technology, using a web-
based randomization system, including stratification for
age (4–10 years and 11–17.5 years) and study center.
The randomization lists are distributed to, and stored at,
each respective study site’s pharmacy department which
allocates the participants to either BoNT-A injections or
saline (allocation ratio 1:1). The appropriate solution of
BoNT-A or saline will then be prepared at the pharmacy
and delivered in syringes to the researchers. In a pilot,
we found that the two solutions were indistinguishable
regarding smell and appearance. Accordingly, trial par-
ticipants and their caregivers, and all other persons in-
volved in treatment and outcome assessment are blinded
to group allocation. The procedure for emergency
unblinding is included in the study’s Trial Master File
(TMF) and will be carried out by the responsible phar-
macy in cooperation with coordinating national investi-
gator of the study.
Treatment procedure
The dosage of BoNT-A (Botox®; Allergan) used in this
study is based on one systematic review [23], one original
paper [24] and two international expert consensus papers
[25, 26]. The total maximum body dose of Botox® will be
420 Units. Maximum dose per injection site will be 50
Units. The gastrocnemius muscle will receive 5–6 Units
Botox® per kilogram, with a maximum of 180 Units in
each leg. The soleus muscle will receive 2 Units Botox®
per kilogram with a maximum dosage of 60 Units in each
leg. The maximum injected volume per injection site will
be 0.5 ml of a solution of 100 Units of Botox® in 1 ml 0.9%
saline, or 0.9% saline only (placebo). The placebo dose will
be the same dose in milliliters as the reconstituted Botox®.
The injections are given using ultrasound-guidance, allow-
ing quick visual identification of the target muscle and
exact localization of the needle in the desired position.
The participants will receive the treatment using local
anesthesia and conscious sedation with oral or nasal
benzodiazepines if desired by the participants and their
caregivers. The sedation procedures will be given in ac-
cordance with standard guidelines used in each of the par-
ticipating centers.
Study visits
Flow of participants and the timeline is presented in
Fig. 1. The primary endpoint will be 12 weeks post injec-
tion, when a clinical effect can be expected. Outcomes at
4 and 24 weeks post injection will also be evaluated in
order to control for the specific paralyzing effect on the
muscle [27] and a possible delayed functional effect [15],
respectively. Thus, the outcome measures will be
assessed at baseline and 4, 12 and 24 weeks after injec-
tions (Fig. 1: P1, P2 and P3).
At each visit, there will be a face-to-face session with the
child and the parents to map the period from the last visit.
In addition, any AE will be recorded in the eCRF, and action
taken according to procedure included in the TMF. All
changes in concomitant medication (including vitamins,
herbal preparation and other “over-the-counter” drugs) used
by the patient will also be recorded in eCRF. Moreover, the
content and intensity of supportive therapy, such as specific
exercise programs, physiotherapy and ankle-foot orthoses
(AFO) will be recorded in detail. Since such supportive ther-
apy is not standardized in Norway and, therefore, will vary
between centers according to their clinical guidelines, strati-
fication by center at randomization is made.
At baseline, the following subject characteristics are re-
ported: GMFCS level, CP distribution (uni/bilateral) num-
ber of previous BoNT-A treatments in calf muscles,
previous surgeries to the lower limbs, age and gender. At
each visit, spasticity is evaluated using the clinical Tardieu
Test [28], and weight and height are also registered.
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Primary outcome measure
The primary outcome measure is energy cost (EC) in J/
kg/m during walking, obtained from a 5-Minutes Walk
Test (5MWT) at a self-chosen comfortable speed [29]
with simultaneous gas-exchange measurements [3]. It
has been reported that children with CP have an EC
during walking corresponding to 6.84 J/kg/m (standard
deviation (SD) 2.0 J/kg/m) and that the smallest detect-
able difference of this measure is 0.464 J/kg/m (or 6.8%)
[29]. Taking this information into consideration we de-
fined a 10% improvement in the intervention group (i.e.,
0.684 J/kg/m) to be clinically significant. For children
using an AFO on a regular basis, this assessment will be
carried out both with and without the orthosis.
Secondary outcome measures
Secondary outcomes are:
1. Walking capacity, reflected as (a) distance walked
during a 1-Minute Walk Test (1MWT) where the
participant is walking as fast as possible without run-
ning [30] and (b) perceived exertion during walking
assessed by the use of the OMNI Rating of Perceived
Exertion scale (OMNI-RPE), measured after the
5MWT at comfortable speed and after the 1MWT
[31]. In the OMNI-RPE the children are asked to
rate their perceived exertion on a 10-point scale (0–
10) by the use of a series of four pictures of a child
walking up a hill becoming progressively more and
more tired. It is validated for children with CP [31]
2. Habitual physical activity, measured by two body-
worn accelerometers (Axivity Ltd.); one at the thigh
and one at the lower back, over a period of seven
consecutive days following visits at baseline, and at
P1, P2 and P3. The accelerometer as a measure of
habitual physical activity is reported to be feasible in
children with CP [32] and valid in reflecting time in
sitting, lying, standing and walking [33]. In our study,
two accelerometers are used in order to differentiate
between sitting and lying
3. Perceived change in performance and satisfaction,
measured by The Canadian Occupational
Performance Measure (COPM). The COPM is used
to detect changes in self-perceived activity perform-
ance in the areas of self-care, productivity (i.e.,
school) and leisure. At baseline, the instrument will
Fig. 1 Flow of participants through study. Figure 1 shows the flow of participants through the study according to the Consolidated Standards of
Reporting Trials (CONSORT) guidelines
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be administered as a semistructured interview that
focuses on activities that the participant wants,
needs or is expected, to perform. Through the inter-
view, the child will be allowed to identify and
prioritize up to three “problems” related to gross
motor function. Performance and satisfaction related
to each problem are then scored on a 10-point or-
dinal scale (1–10), where a higher score reflects
greater performance and satisfaction, respectively.
Rescoring will be made at P1, P2 and P3. The COPM
in its original version, as well as in the Norwegian
translation, has been found to be a valid, reliable and
responsive outcome measure ranging from satisfac-
tory to excellent [34]
4. Pain during the last 2 weeks will be assessed
stepwise. Participants will be asked to record all pain
sites on the body outline from the Brief Pain
Inventory (BPI), the Norwegian version [35] and to
respond to the two questions on pain (“how much”
and “how often”) from the Child Health
Questionnaire (CHQ, Norwegian version) [36]. To
capture the level of pain interference with function,
pain interference with the three BPI items general
activity, walking and sleep will be recorded on 0 (no
interference) to 10 (complete interference) rating
scales. In cases of calf pain, identical recordings will
be made for the right and left leg separately and the
child will be asked to indicate maximum calf pain
intensity on the Faces Pain Scale-Revised (FPS-R)
[37]. To secure the view from both parents and the
young people with CP separately, parents will re-
spond to a questionnaire while their child is occu-
pied with test procedures, and the young people
with CP will give their responses in an interview.
In addition, at all four visits, spasticity in the calf mus-
cles will be assessed by the clinical Tardieu Test [28] and
passive range of motion in the ankle joint will be mea-
sured by a manual goniometer. Moreover, during the
5MWT and the 1MWT, concurrent heart rate monitor-
ing and accelerometry will be obtained. All data collec-
tion will be carried out by trained assessors and pilots
on all outcomes were made before trial start. Collected
data will be entered on site into each participant’s eCRF
by the assessors and the data will be checked by the data
manager in the study after each entry.
Sample size and power
Sample size calculations were performed for a two-
sample (two-sided) t test for comparing the change in
the primary outcome measure, EC, from baseline to
12 weeks post intervention between the two groups. The
estimate was based upon a mean difference in change of
0.684 6.84 J/kg/m [29]. The SD of change was set at 1.0
based on other intervention studies [3, 38], in which the
SD of change is found to be approximately half of the
baseline SD [29], and assuming a baseline SD of 2.0 J/
kg/m [29]. Thus, to detect a clinical significant improve-
ment in the primary outcome, measure, reflected as a
10% decrease in EC (from 6.84 J/kg/m), with a power of
80%, using a two-sided t test and a 5% significance level,
a sample size of 32 children/adolescents per group is ne-
cessary. Allowing for a dropout of 30%, 48 children/ado-
lescents are needed. In practice, the test will be
performed as a post-hoc test for a linear mixed model
(LMM), but the sample size calculation for the t test for
the change from baseline to post is assumed to be con-
servative in that respect.
Statistical analysis
The statistical analysis for the primary aim will be per-
formed using a LMM including data from baseline and 4,
12 and 24 weeks post intervention. The test for difference
in change in the primary outcome measure from baseline
to 12 weeks between the treated and placebo group will
be done using a post-hoc test following the LMM. Age,
GMFCS level, number of prior BoNT-A treatments and
study center will be considered as potential covariates. A
similar model will also be used to study the secondary out-
come measures. The LMM handles missing data for the
outcome measure. Nonparametric tests will be used to
test for a between-group difference in change score for
secondary outcome measures expressed with ordinal data,
and for scalar data in case the requirements for the para-
metric tests are not met. The effect size will be expressed
as mean difference between the groups in change from
baseline to 12 weeks with a 95% confidence interval.
In addition to investigating the independent effect of
BoNT-A on walking, the associations between the change
scores of the primary and secondary outcome measures
will also be studied.
The level of significance is set to 0.05 and no formal
adjustments for multiple testing will be carried out.
A complete plan for the analyses of the outcome mea-
sures will be made before unmasking group adherence. Re-
sults will be reported according to the Consolidated
Standards of Reporting Trials (CONSORT) Statement [39].
Discussion
Despite the common use of BoNT-A, the evidence for
beneficial functional effects on walking in children with
spastic CP is insufficient and there is, therefore, a strong
need for high-quality RCTs that can fill this knowledge gap.
The ethical concerns in this study are related to the injec-
tions of placebo (saline) into the leg muscles of children in
the control group. Such injections can be as painful as
BoNT-A injections despite the use of local anesthesia and
mild sedation. Deep sedation can usually be given to
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anxious children or to children who experience pain during
the treatment procedure. However, the Ethical Committee
did not approve the use of deep sedation to children in the
control group. Since most patients are treated without deep
sedation, this restriction is not expected to affect the num-
ber of participants substantially. In addition, the regular
treatment of children in the control group will be delayed
by at least 6 months. With respect to the latter, however, a
recently published paper by Hastings-Ison and co-workers
[40]. comparing 4 versus 12 months’ treatment frequency
of BoNT-A injections, recently reported no significant dif-
ference in passive ankle dorsiflexion. Thus, the results of
that study, as well as our clinical experience, and in the per-
spective of the total BoNT-A treatment of these children,
this postponement is unlikely to affect the long-term
outcome.
Moreover, it may be considered an ethical issue that
more than half of the children with GMFCS levels I and
II are treated with this drug, and a proportion of them
require deep sedation during treatment if the drug does
not have the assumed effects. Therefore, it seems to us
that the use of placebo in this study is in line with gen-
eral requirements for better evidence of pediatric treat-
ment, including high-quality RCTs [41].
This current trial has several strengths. The study is
comprehensive, including a relatively homogenous popu-
lation of children classified with GMFCS levels I and II.
Moreover, the intervention comprises single-level injec-
tions in the calf muscles only. Including participants with
multilevel injections as well would challenge the interpret-
ation of the results. Finally, the evaluation of effect is com-
prehensive and includes objective standardized tests and
measures on both the impairment and activity level ac-
cording to the ICF [42]. Effect on participation is not eval-
uated explicitly, since we consider that the follow-up time
of 24 weeks will be too short to expect significant clinical
changes in this dimension. Nonetheless, the COPM may
give some indications of possible effects on participation.
The randomization procedure is stratified according to
age and study center. The age range of the participants is
quite wide, from 4 years to 17.5 years. Since there is pos-
sibly an effect of age, due to assumed structural and func-
tional changes in the muscle as a result of growth and
spasticity [43], two age groups are created (4–9 and 10–
17.5 years) to make sure that age is evenly distributed
among BoNT-A and placebo groups. The differences be-
tween the study sites regarding supportive therapy will be
controlled through the stratification of the randomization.
Moreover, the detailed description of this therapy applied
to each participant will enable us to correct for potential
differences in supportive therapy.
A main challenge in the project is recruitment of partic-
ipants; the patient base is small, and the possibility of re-
ceiving placebo may cause some reluctance to participate.
In case of slow recruitment, we plan to implement one
more study site in a fourth health region in Norway.
Trial status
This trial started recruiting participants medio September
2015 and recruitment period is estimated to be 3 years.
Results are, therefore, to be expected during spring 2019.
All personnel who have contributed significantly with the
planning and performance of the study (Vancouver con-
vention 1988) may be included in the list of authors.
In addition, to be submitted for publications in peer-
reviewed journals and communicated to the participants,
the results of this study will also be submitted to the
Competent Authority and the Ethics Committee accord-
ing to EU and national regulations.
Additional file
Additional file 1: SPIRIT Checklist. (PDF 129 kb)
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